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MitostasisCardiovascular diseases are the leading cause of death inmost developed nations. While it has received the least
public attention, aging is the dominant risk factor for developing cardiovascular diseases, as the prevalence of
cardiovascular diseases increases dramatically with increasing age. Cardiac aging is an intrinsic process that
results in impaired cardiac function, along with cellular and molecular changes. Mitochondria play a great role
in these processes, as cardiac function is an energetically demanding process. In this review, we examine
mitochondrial dysfunction in cardiac aging. Recent research has demonstrated that mitochondrial dysfunction
can disrupt morphology, signaling pathways, and protein interactions; conversely, mitochondrial homeostasis
is maintained by mechanisms that include ﬁssion/fusion, autophagy, and unfolded protein responses. Finally,
we describe some of the recent ﬁndings in mitochondrial targeted treatments to help meet the challenges of
mitochondrial dysfunction in aging.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The heart is a highly metabolic organ that is reliant on the mainte-
nance of cellular-energetic homeostasis, precisely regulated mitochon-
drial dynamics, and optimal mitochondrial function. Mitochondria are
important determinants of cellular homeostasis and longevity since
they are the main producers of cellular ATP and play a vital role in
regulation of apoptotic death pathways in many tissues. Due to its
high energetic demand and high density of mitochondria, the heart is
especially vulnerable to mitochondrial dysfunction via structural
disruption, energetic ﬂuxuations, and mitochondrial signaling. Cardiac
senescence is accompanied by a general decline in mitochondrial
function, clonal expansion of dysfunctional mitochondria, increased
production of reactive oxygen species (ROS), suppressed mitophagy,
and dysregulation of mitochondrial quality control processes such a
fusion and ﬁssion [1–4]. These detrimental alterations in mitochondrial
function have been widely correlated with several age-related cardiac
diseases, as will be described below. The mechanisms responsible for
age-related mitochondrial dysfunctions in cardiac tissue are only par-
tially deﬁned and it is not yet clear the extent to which mitochondrial
dysfunction is directly linked to aging [5]. Nevertheless, the information
belowwill illustrate that there is abundant evidence thatmitochondrial
function is intimately tied to cardiac health and, likely, largely related to
cardiac aging.ashington School of Medicine,
–7470, USA.
quarles@gmail.com
w.edu (L. Gitari),2. Mitochondrial energetics in cardiac aging
Given the high energetic demand of the heart, it is not surprising
that age-related defects inmitochondrial bioenergetics have been relat-
ed tonormal cardiac aging [5–7].Many factors contribute to the reduced
energetic capacity of the cardiac mitochondria including increased ROS,
mutation anddeletions in themitochondrial genome, and dysregulation
of proteostasis and mitochondrial biogenesis [5–9]. In rodent models,
the total mitochondrial content does not change in liver and brain
with age, however, the activity levels of components of the electron
transport chain decrease [10].
It has been documented that the activity ofmitochondrial respiratory
chain complexes declines with age in skeletal muscle [11], brain [12],
and heart [6], particularly in complex I and IV [6,13]. Complexes II, III,
and V remain less affected by age in cardiomyocytes [6,9]. Differences
in the reported activity levels of complex III in aging heart may be due
to the inclusion or exclusion of two separate populations of cardiac
mitochondria, interﬁbrillar (IFM) and subsarcolemnal (SSM), a unique
aspect of cardiac structure. Of these two populations, complex III
activity may only decrease in the IFM with aging [14]. The decreased
activity of complexes I and V (and possibly III and IV) may be partially
compensated for by increased expression of the mitochondrial genes
within those complexes in adult mice, but this overexpression was
reversed in aged mice [15].
Levels of mitochondrial respiratory proteins and other key proteins
involved in mitochondrial metabolism decline in the old heart, includ-
ing those in fatty acid metabolism. Conversely, glycolytic metabolic
pathways as well as extracellular structural proteins increase signiﬁ-
cantly with age [16]. Increased expression of glycolytic proteins, togeth-
er with a decline in fatty acid oxidation, TCA cycle, and amino acid
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similarity to heart failure in younger individuals [17,18]. As described in
a subsequent section, treatment of old mice with CR or rapamycin
reverses this metabolic substrate shift in the heart, restoring a greater
dependence on fatty acid oxidation and mitochondrial function [16].
As the heart has uniquely high and continuous energetic requirements,
many of the energetic and metabolic changes seen in cardiac aging and
failure may be more apparent in the heart than in other organs.
3. ROS, DNA damage and the aging heart
Mitochondria are the main source and target of ROS produced as
by-products of cellular respiration [19,20]. ROS production increases
with age and higher ROS content limits proper functioning of macro-
molecules and signaling pathways [21]. The mitochondria free radical
theory of aging (MFRTA) hypothesized that age-related increases inmi-
tochondrial ROS resulted in accumulation of mtDNA mutations and
oxidized proteins and lipid that impaired mitochondrial respiratory
(RC) efﬁciency, leading to further ROS production in a viscous cycle
[22–24]. Many studies showed data consistent with this theory, includ-
ing increased ROS production, increases in mitochondrial DNA
(mtDNA) mutations, and respiratory chain dysfunction in aging tissues
[25–31,6,32–35]. Decreased mtDNA quantity and deteriorating replica-
tion ﬁdelity with age contributes to an accumulation of dysfunctional
mitochondria often resulting in pathological outcome [36–40]. Howev-
er, there is increasing recognition that ROS and ROS signaling have ben-
eﬁcial roles, and many studies of mouse models in which cytoplasmic
antioxidant enzymes are reduced or increased have failed to support a
causal connection to aging [41]. The study that is most supportive of
the mitochondrial variant of the free radical theory of aging is of trans-
genic mice that express catalase that is targeted to mitochondria
(mCAT); these mice has increased lifespan [42] and numerous reports
of resistance to diseases of aging [43]. Most relevant to this review,
mCAT mice have a phenotype of delayed cardiac aging that includes
both functional and molecular parameters [44]. Furthermore, mice
with mutation in the mitochondrial Polg exonuclease proofreading
domain (PolgD181A) have elevated mitochondrial DNA mutations and
deletions, exhibit a progeria phenotype and can develop cardiomyopa-
thy leading to congestive heart failure [45]. This cardiomyopathy is
attenuated in mCAT mice, indicating that this phenotype is partly
mediated by mitochondrial oxidative stress [46].
4. Mitochondrial structural changes with aging
In severalmodel systems, and in humans, evidence suggests that the
structure of mitochondria in the heart is disrupted by the aging process.
Studies in human and hamster hearts show that mitochondria may
increase in size with age [47,48]. Electron microscopy has been used to
demonstrate a disrupted morphology of mitochondria with age in
mice [49]. It has been shown that themouse cardiac innermitochondrial
membrane displays a loss of cristaewith aging [50], although cristamor-
phology does not appear to change with age in Fischer 344 rats both in
situ and in isolated subsarcomal and interﬁbrillar mitochondria [51].
Mitochondrial structure is intimately associated with functional in-
tegrity and the cristae provide essential scaffolding for RC complexes;
thus it would be no surprise that alterations in mitochondrial structure
might be integrally related to the age-related decline in mitochondrial
activity. Indeed, reversing the loss of youthful mitochondrial structure
with age may result in improved electron transport activity [52].
4.1. Cardiolipin in the aging heart
The inner mitochondrial membrane contains cardiolipin (1′- [1,2-
diacyl-sn-glycero-3-phosphoryl]-3′- [1″,2″-diacyl-sn-glycero-3″-phos-
phoryl]-sn-glycerol; 1,3- diphosphatidylglycerol), which is almost en-
tirely absent from the rest of the mammalian cell [53–55]. Cardiolipin(CL) was ﬁrst puriﬁed from beef heart in 1942 and has since been clas-
siﬁed as a tetra–acyl phospholipid essential for the structural integrity
of themitochondrialmembrane [56] (reviewed in [53]). The acyl chains
on CL can vary depending on which kingdom, species and tissue is
investigated [57–60] and what diet is being consumed [61,62].
CL has an essential role in maintaining optimal mitochondrial struc-
ture and function through its ability to maintain curvature of cristae,
supporting the assembly and interaction of mitochondrial respiratory
chain complexes and supercomplexes, modulating and maintaining
the proton gradient, and preventing apoptosis (reviewed in [63,64]).
Recent studies have begun to help clarify some of these complex inter-
actions between cristae structure, CL, respiratory complexes and the
proteins that facilitate their assembly [65,66]. A considerable body of
evidence [54,67–70], with rare exception [71] suggests that CL is selec-
tively lost and/or remodeled in aging mitochondria.
Modiﬁcation or restoration of CL content has been proposed as a
method of reducing age-associated declines in mitochondrial function.
Age-dependent loss of CL may be due to oxidative stress [72], which
can be due to extrinsic ROS or by peroxidase activity of cytochrome C
that is closely associated with CL [73]. Prevention of peroxidation of CL
may attenuate or abrogate mitochondrial dysfunction [73]. In the
brain, melatonin might help to preserve the structural integrity of
cardiolipin by preventing age-related peroxidation of the cardiolipin
[74]. This was observed alongside other improved parameters of mito-
chondrial aging in the brain and suggests that preservation of intact
cardiolipin is an avenue of abrogating age-related declines inmitochon-
drial function. Similarly, Paradies and colleagues have reported that
acyl-carnitine supplementation in aged rats restored CL levels to that
of young controls, and that some CL-dependent processes were
improved [68,75].
Barth syndrome is an example of CL disease with cardiomyopathies
being the most deadly symptom. In Barth syndrome, tafazzin, another
protein located in the mitochondria, is mutated or lost. CL is modiﬁed
into its ﬁnal 18:2 form frommonolysocarlipin (MLCL) by adding and re-
moving acyl chains in two different tafazzin-dependent mechanisms
[76]. The exact mechanism is still unknown for how tafazzin and CL
interact, but the disease state suggests an important relationship
between the two.
More recently, it has been suggested that the protective effects of
mitochondrial targeted SS-31 peptide is due to its afﬁnity for CL and
the prevention of cytochrome C peroxidation (see the section on
Cardiolipin-Targeted Therapies, below).5. Dietary intervention and the aging heart
CR, the reduction of total calories without nutritional deﬁcits, is the
longest studied and most reproducibly successful method of extending
lifespan and improving healthspan inmodel organisms. CR exerts some
of its effects through modulating TOR signaling (mTORC1 in particular
in mammals), and seems to have a wide range of effects, including
modulation of tissue maintenance (reviewed extensively in [77]). In
multiple organisms, including humans, rodents, and monkeys, chronic
CR delays the onset of cardiac aging. This can be seen as a reduction of
aging-associated cardiac functional decline, cardiac hypertrophy, and
cardiomyopathy [16,78–82].
CR protects against cardiomyopathy, at least in part, by reducing
age-associated apoptosis. This is partially accomplished by a reduced
susceptibility to DNA damage, improved DNA repair, and apoptosis-
related gene expression alterations [80,83]. Expression of genes
involved in numerous other processes important for mitochondrial
function in aging are also modulated by CR, including extracellular
matrix maintenance, inﬂammation, oxidative phosphorylation, and
glucose and fatty acid metabolism [16,83]. Other protective effects of
CR in themyocardium include the reduction of ﬁbrosis and perivascular
collagen deposition, reduced vascular inﬂammation and left ventricular
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[83–85].
While it is unknown exactly how CR modulates cardiac aging, an
attractive hypothesis is that limited nutrient and energy availability
allows tissues to switch to a somatic maintenance state that may
include optimization of existing cellular resources. For example, Drake
and colleagues (2013) found that proliferative rates in heart, while
low in controls, were further reduced by life-long CR (measured by
DNA synthesis) while measures of mitochondrial biogenesis were
maintained [86,87]. Short term (10weeks) CR has been shown to result
in improved cardiac function accompanied by a 30% reduction in pro-
tein turnover rates, and remodeling of the cellular and mitochondrial
cardiac proteome and metabolome toward an abundance proﬁle more
similar to that of young mice, as well as with lower oxidative damage
[16].
Oxidative stress increases with age, concurrent with a decreasing
ability to prevent or recover from oxidative stress in the heart [88].
While some evidence suggests that mitochondrial dysfunction may
not be due to damage from age-associated ROS alone [25], modulation
of this stress either by direct targeting of catalase to the mitochondria
(mCAT) [42,89], or by CR [16,79,81,90] results in improvements in
cardiac function and inmolecular changes indicative of an improved re-
sponse to oxidative stress. For example, long-term, but not short-term,
CR has been shown to dramatically reduce mitochondrial H2O2
production while lowering oxidative damage to mtDNA [91]. A clear
understanding of the mechanisms of CR enhancement of cardiac mito-
chondrial function should provide greater insight into future protective
intervention strategies.
6. Signaling pathways
Modulation of cardiac health and aging, including the effects of CR, is
mediated through several signaling pathways, the best characterized of
which include mTOR and Insulin-like Growth Factor signaling and
downstream of these, regulation of histone acetylation by sirtuins.
6.1. mTOR pathway
Rapamycin inhibits mTOR (mechanistic target of rapamycin) and is
the best studied CR mimetic. mTOR modulates several important
growth and cellular quality control mechanisms including ribosomal
biogenesis, autophagy, lipid synthesis, and protein translation
(reviewed in [92]). Following the National Institute on Aging Interven-
tion Testing Program's [93] demonstration of enhanced longevity after
chronic rapamycin treatment of mice [94], several other publications
have demonstrated that long-term rapamycin treatment of mice im-
proves healthspan measures and/or extends lifespan [95,96]. Inhibitors
of TOR (both genetic and pharmacological) also extend lifespan and
healthspan in other model organisms including ﬂies [97], nematodes
[98,99], and yeast [100,101]. The liver, adrenal glands, tendons, bone
marrow, and heart have all been observed to be affected by rapamycin
during aging [102,103].
Rapamycin confers functional beneﬁts to the aging heart. Wilkinson
and colleagues found thatmanymeasures of healthspanwere positively
affected by life-long rapamycin treatment in 20–22-month-old geneti-
cally heterogeneous mice. In the heart, they found that the incidence
of nuclear atypia was reduced in rapamycin treated animals [102].
Pressure-overload-induced cardiac hypertrophy in young mice is
reduced by rapamycin [104]. Recently, it has been shown that short-
term (10–12 weeks) rapamycin treatment in late-life reversed age-
related cardiac functional declines in mice, including improvement in
systolic and diastolic dysfunction, and a reversal of cardiac hypertrophy
[16,105]. Investigators at the Buck Institute reported that this was ac-
companied by a reduction in age-related sterile inﬂammation [105],
while our laboratory showed that rapamycin recapitulated the CR effect
of remodeling the old heart proteome to a more youthful abundance ofproteins associatedwith youngmitochondrial function (ETC., TCA cycle,
fatty acid metabolism) and decreased abundance of glycolytic pathway
proteins [16]. These results may point to proteomic and metabolic
remodeling as a mechanism behind the cardiac functional beneﬁts
granted by rapamycin.
6.2. Insulin-like growth factor
The insulin/IGF-1 signaling pathway helps regulate cellular prolifer-
ation, survival, and autophagy [106,107]. This pathway is one of the best
characterized determinants of lifespan, as deﬁciency in insulin/IGF-1
signaling is associated with increased lifespan in both invertebrate and
vertebrate models of aging and IGF-1 activity is also down regulated
in CR [108,109]. In general, IGF-1 has been shown to be cardio protec-
tive, allowing for suppression of ROS and autophagy in the cardiovascu-
lar system [107,110–112]. Notably, reduction in insulin/IGF-1 signaling
improved cardiac performance at advanced age in Drosophila [113]. In
contrast, an age-dependent decline in serum IGF-1 correlates with an
increased risk of heart failure in humans [114]. It has therefore been
proposed that treatments to increase IGF-1 signaling, including growth
hormone therapy, may actually be beneﬁcial in some patients
with heart failure [115]. Thus, much remains to be learned before we
understand the full role the IGF-1 pathway plays in cardiac aging.
6.3. Sirtuins
Sirtuins (Sirt) are a family of proteins deacetlylases. There are seven
members of the family, with Sirt3, Sirt4, and Sirt5 being targeted to the
mitochondria [116,117]. Sirt3 in particular has been studied in the car-
diovascular system and has been shown to prevent apoptosis, interact
with nutrient sensing, and post-translationally modify proteins, while
also being the only Sirt to be linked to an increase in human lifespan
[118,119]. Sirt3 overexpression leads to a decrease in cardiac hypertro-
phy via activation of Foxo3a-dependent defenses, while the loss of Sirt3
in cell lines andmice, leads to an increase [119,120]. Sirt3 helps prevent
apoptosis by inhibiting upstream effectors of Bax, including Ku70 [121].
Other studies have shown that Sirt3 reduces levels of ROS by regulating
antioxidant enzymes such as SOD2,MnSOD, and catalase [116,118,119].
By responding to mitochondrial NAD status, Sirt3 has a key metabolic
regulatory role; this is shown mice lacking Sirt3 by reductions in com-
plex I and III of the ETC., decreased in fatty acid oxidization, and a
glycogenic state that leads to accelerated cardiac aging [117,122,123].
Sirt3 is thought to be the main deacetylase in the mitochondria, which
is supported by the fact that when Sirt3 knockoutmice are investigated,
there is an increase in acetylation in the ETC., especially complex I [120].
Sirt3 is able to maintain mitochondrial integrity by deacetylating
cyclophilin D, a protein that helps open the mitochondrial permeability
transition pore [124]. Calcium induced mitochondrial swelling was
increased in Sirt3 deﬁcient cells [123]. Resveratrol has been shown to
activate Sirt3 by a variety of labs [125,126]. This interaction has been
linked to both the NF-ΚB signaling and TGF-β/Smad3. With the induc-
tion of NF-ΚB pathway, it is suggested that apoptosis is inhibited by
increasing the expression of SOD2 and Bcl2, while decreasing the Bax
[125]. In models of mouse TAC surgery, when resveratrol was given,
the mice had less ﬁbrosis, which was linked to the TGF-β/Smad3
pathway preventing the transition of myoblasts to ﬁbroblasts [126].
Sirtuins that are not targeted to the mitochondria have also been
linked to the heart and aging. Overexpression of Sirt1 caused early
heart failure with a decrease in oxidative respiration and an increase
in degenerated mitochondria [127]. Some have suggested that this in-
teraction might be signaled through ALD2, a mitochondrial encoded
gene whose overexpression accentuates myocardial remodeling and
contractile dysfunction in aging [128]. Sirt7 deﬁcient mice have short-
ened lifespans demonstrating cardiac hypertrophy and inﬂammatory
cardiomyopathy [119]. Sirt7 deacylelates a protein involved in
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shown to increase in primary cultured cardiomyocytes [130].
7. Proteostasis and cardiac aging
Protein homeostasis (proteostasis) is the equilibrium between pro-
tein synthesis, maintenance, and degradation. Maintaining the prote-
ome is integral to maintaining cellular functions and organismal
health, and many studies have demonstrated that inability to remove
unwanted proteins and/or replace them with functional proteins can
be detrimental [131]. Age-related conditions are generally accompanied
by a decline in protein quality control mechanisms, thereby causing
changes in the global proteome. A few well studied examples include
cardiac dysfunction [132,133], neurodegenerative disease [134], cata-
racts [135], and sarcopenia [136–138]. While dysfunction of protein
quality control mechanisms is a hallmark of aging, interventions that
improve protein quality can enhance organismal health and longevity
[131,134,139,140]. For example, the characteristic accumulation of
damaged proteins and declines in mitochondrial respiratory capacity
with age have been alleviated in models with over-expression of
mitochondrial-targeted catalase [42], CR [141,16], reduced IGF-1 signal-
ing [142,143], and rapamycin treatment [92,16]. That this mechanism
has been implicated in interventions that inhibit mTORmay not be sur-
prising, given its known effects on protein translation and degradation
(see above). Collectively, these studies suggest that dysfunctional
proteostasis has a causative role in aging and that restoration of protein
homeostasis machinery is protective against aging and age-related
disease. However, many mechanistic question of how these processes
extend lifespan and healthspan remain unanswered. Fortunately,
these processes are receiving increased attention as their roles are
becoming more recognized [131,140].
The aging cardiac proteome recapitulatesmost hallmarks of the aged
cellular proteome including the appearance of protein aggregates
and lipofuscin, increased protein oxidation and damage, increased
ubiquitination, and declines in autophagy and the ubiquitin proteasome
system [16,144–146]. All of these changes are consistent with altered
proteostasis during cardiac aging. Consistent with this, we have
observed increased protein ubiquitination and carbonylation in old
hearts [16]. However, this is not accompanied by increased protein
turnover in old hearts; in fact, slower turnover is observed in aging
rodents [16,147]. Together, observation of increased protein
ubiquitination and carbonylation, but decreased protein turnover is
suggestive of a defect in cardiac proteostasis. These changes may owe
to an underlying decline in major protein quality control systems with
age, which in turn leads to low quality and damaged proteins which
become increasingly unable to perform their roles efﬁciently. Given
the importance of mitochondrial energetics in the heart, mechanisms
of mitochondrial quality control are particularly relevant to cardiac
aging. The next sections focus onmitochondrial ﬁssion, fusion, unfolded
protein response and autophagy as critical components of protein
quality control.
8. The role of fusion/ﬁssion dysregulation in Age-related cardiac
bioenergetics deﬁciencies
As noted above, mitochondrial dysfunction, and in particular, bioen-
ergetic deﬁciencies are an important hallmark of cardiac aging. Age-
related decline in mitochondrial activity and impaired mitochondrial
dynamics offer a potent explanation for deteriorating cardiac perfor-
mancewith age. Dysregulation of mitochondria quality control process-
es are widely reported in aging and although few studies have focused
on the role of dysfunctional mitochondrial dynamics in cardiac senes-
cence, there is extensive evidence to indicate that healthy cardiac
performance is highly reliant onprecise balance ofmitochondrialﬁssion
and fusion.Mitochondria are highly motile organelles that constantly change
morphology, fuse, divide, and move depending on energy demands
and integrity of individual mitochondria. Following ﬁssion, segments
of mitochondrial that are dysfunctional, sensed as reduced membrane
potential, are targeted for mitophagy [148]. This homeostatic process
helps to ensure optimal mitochondrial quality and supply of ATP to
meet energy demand [149]. The key regulators of mitochondrial
dynamics, Mfn1, Mfn2, Opa1, hFis1, Drp1, Mff, MiD49, and MiD51
show high expression in normal cardiac tissue, consistent with their
pivotal role in mitochondrial dynamics and bioenergetics [150,151].
Genetic defects of proteins regulating fusion/ﬁssion are correlated
with severe alterations in mitochondria morphology, decreased
mtDNA integrity, increased oxidative stress, susceptibility to apoptosis,
and metabolic dysregulation [152]. Mitofusion 1 and mitofusion 2 null
mice are embryonic lethal, while knock-downs have fragmented
mitochondria, characteristic of declining mitochondrial fusion; mfn1
deﬁciency is observed in giant cells similar to those present in age-
related cardiac hypertrophy [153]. Genetic aberrations of mfn1 and 2
are consistent with increased respiratory dysfunction and higher
frequencies of mtDNA mutations [154]. Dysregulation of ﬁssion may
cause permeabilization of the mitochondrial membrane and release of
caspase-3, a key modulator of myopathic apoptosis observed in
senescent heart [155–157] that can trigger several other cytosolic
death pathways [158,159] likely similar to those observed in heart
failure [155] and possibly other cardiac pathologies.
Mitochondrial fusion is regulated by Mfn1, Mfn2, and Opa1. Opa1
mice missing one allele, develop cardiomyopathy late in life, and the
acetylation of Opa1 has been linked to the development of heart disease
when mice are pharmacologically, dietary, or surgically stressed [160].
The general loss of Opa1 in MEFs has been shown to give fragmented
mitochondrial populations. Recently, in a ﬂy model, suppression of
Opa1 led to worsened contractility and increased dilation. These chal-
lenges were traced back to increased ROS production, and could be re-
versed by increasing ROS scavenging proteins [161]. Cardiac speciﬁc
Mfn1/Mfn2 KOs have been shown to develop early onset heart disease
[162]. Mfn1/2 are found on the outer mitochondrial membrane, where
they can make hetero- or homo-dimeric interactions with neighboring
mitochondria. Mfn1/2, unlike Opa1, are increased in some forms of
heart failure [163]. Mfn1/Mfn2 plays a large role in autophagy that is
often difﬁcult to separate from their roles in fusion, which is an area of
intense research. Mfn2 plays a key role in mitochondria–sarcoplasmic
reticulum tethering for calcium signaling. In fact, loss of outer mem-
brane mitofusins (MARF) led to fragmented mitochondria with higher
ROS, which was repaired by increasing XBP1 expression, a protein in-
volved in ER stress [161].
Mitochondrial ﬁssion is managed by Drp1, Fis1, and Mff. Drp1 is
localized to the cytosol until it is attracted to the mitochondrial surface
for a ﬁssion event [164]. Drp1 has recently been suggested to help
protect cardiac cells from IR injury by allowing them to be less reliant
on oxidative phosphorylation and delaying or suppressing apoptosis
[164,165]. The depletion of Drp1 in cardiomyocytes or in mouse hearts
leads to mitochondrial dysfunction and heart disease, respectively
[166]. A study by Ikeda et al. demonstrated that unchecked mitochon-
drial fusion, by Drp1 knock out was just as detrimental as is unchecked
ﬁssion [166]. MiD49/MiD51 has been shown to recruit Drp1 to the mi-
tochondrial surface [151,167,168]. Fis1 and Mff perform this role, but
MiD49/MiD51 only recruit to the mitochondria while Fis1 and Mff are
suggested to recruit to the peroxisome as well [151]. MiD49/MiD51
overexpression can make up for Drp1 recruitment in Fis1−/−/Mff−/−
cells to a normal phenotype [151].
Despite the recent illumination of the roles and mechanisms of ﬁs-
sion and fusion, challenges remain in studying these processes in
aging cardiac tissue. Much of what is known about mitochondria dy-
namics and its relationship to energetic deﬁciencies in the aging heart
comes from studies of cultured cardiomyocytes and surgically stressed
hearts, not from aging hearts.
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Autophagy is a major quality control pathway essential for the re-
moval of unwanted proteins, macromolecules and organelles to main-
tain mitochondrial function. Cellular degradation involving lysosomes,
a singlemembrane vesicle containing enzymes for the digestion ofmac-
romolecules, is generally categorized under the umbrella term “autoph-
agy” [140]. There are three major ways by which proteins can be
delivered to a lysosome for degradation, deﬁning the primary categories
of autophagy: macroautophagy, microautophagy, and chaperone-
mediated autophagy. Many details of these processes are outside the
scope of this review, and readers are referred to detailed reviews on
each topic [131,140,144]. This section will focus on macroautophagy
and a mitochondrial-speciﬁc form of macroautophagy termed
“mitophagy”, as these are well characterized processes which may be
important in both mitochondrial function and aging. Knocking down
components of macroautophagy strongly diminishes mitochondrial
function [16,144,145,169], demonstrating that it plays a key role in
mitochondrial maintenance and homeostasis.
Two well characterized regulators of mitophagy are PINK1 and
Parkin [170,171]. PINK1, aka phosphatase and tensin (PTEN)
homologue-induced kinase 1, is a mitochondria-targeted serine/
threonine kinase which serves to protect the cell from mitochondrial
dysfunction and apoptosis [172]. Mutations in this protein are the
most common cause of recessive familial Parkinsonism in humans
[173]. In addition, PINK1 KOmice have severe deﬁciencies inmitochon-
drial homeostasis accompanied by morphological changes in the mito-
chondrial network, increased ROS, and susceptibility to heat shock
[172]. Together this evidence suggests PINK1 has an important role in
Parkinson's disease as well as mitochondrial quality in normal cells,
and possibly plays an important role in aging.
Under healthy conditions, PINK1 is imported into mitochondria via
the TOM complex and is actively degraded bymitochondrial processing
peptidase (MPP) and presenilin-associated rhomboid-like protease
(PARL) [172,174,175]. Upon loss of mitochondrial membrane potential,
PINK1 accumulates on the mitochondrial outer membrane and recruits
Parkin, an E3 ubiquitin ligase, leading to the poly-ubiquitination of
many mitochondrial outer membrane proteins such as Hexokinase I,
VCAC1,MFN1/2, andMiro [176]. These ubquitinated proteins are recog-
nized by autophagy proteins P62, LC3 II, and BNIP3 to promote fusion
with the lysome and clearance of the dysfunctional organelle via
mitophagy [176,177]. Many of the details surrounding this pathway
and the interactions starting at PINK1 and leading up to mitophagy
have been studied in detail and reviewed elsewhere [170,172,176,177].
A few studies have shown that PINK1/Parkin mediatedmitophagy is
important for heart function, particularly in the context of adaptation
and recovery from stress. Parkin KO rats, in contrast to wild type, lack
cardioprotection following ischemic preconditioning [178]. Parkin deﬁ-
cient mice exhibit impaired recovery of cardiac function after sepsis
[179] and have reduced survival and larger infarct size following
myocardial infarction [180]. All of these studies noted that Parkin
deﬁcient animals show disorganized mitochondrial networks, small or
fragmented mitochondria, and an increase in cardiomyocyte cell
death. The infarct study additionally showed that overexpression of
Parkin in isolated cardiomyocytes protects against hypoxia mediated
cell death [180]. Interestingly, protein ubiquitination and LC3II, markers
of mitophagy, were not higher in control mice than in Parkin deﬁcient
animals after sepsis or in the remote zone after myocardial infarction.
However, there was evidence of compensatory increases in
macroautophagy, and possibly an induction of alternative BNIP3-
mediated mitophagy, where Parkin-dependent mitophagy is absent.
Recent work by the Dorn lab suggests that Parkin is not required for
routine maintenance of the mitochondria, but is important in stress-
reactive pathways [181]. This comes with the caveat that the work
was performed on mice that were between nine and ten months old,
well into adulthood, but not necessarily recapitulating aging [181]. Amore detailed review details the role of mitophagy, including the less
known role of BNIP3, in the heart [182].
Even though there were obvious morphological differences in the
mitochondria of Parkin deﬁcient animals, one common observation of
these studies was that under normal conditions there was no apparent
difference in cardiac function compared to wild type mice until ad-
vanced age or animals were ﬁrst subjected to stress. PINK1 KO mice
also show increased vulnerability to ischemic injury [183], but unlike
Parkin deﬁciency, loss of PINK1 has been reported to show signs of car-
diac dysfunction in mice as young as 2 months [184]. By six months of
age, PINK1 KO and heterozygousmutants show increased heart weight,
cardiomyocyte hypertrophy, decreased fractional shortening, and in-
creases in hypertrophic gene expression [184]. Again, in contrast to
Parkin deﬁcient mice under normal conditions, this study also reported
reductions in mitochondrial biogenesis and bioenergetics starting at 2
months of age. Collectively, studies in PINK1/Parkin have shown that
these mediators are important for cardiac function, particularly in
response to stressors, and compensatory increases in other degradation
pathways may alleviate the dysfunction resulting in reduced
mitophagy. However, considerable uncertainty remains in understand-
ing the relative roles of mitophagy vs. other proteostatic processes in
maintaining mitochondrial protein quality control. A key observation
is that half-lives of different respiratory chain complexes and even dif-
ferent proteins within a complex are highly variable, including in the
heart [185,186]. Thiswould not be expected on the basis of the common
perception of mitophagy was a bulk recycling process. It has been sug-
gested, however, that damaged proteins can be preferentially segregat-
ed to the mitochondrial components that are degraded by mitophagy
[187], but there is also evidence that proteosomal activity correlates
with respiratory chain protein half-lives [16,186]. Further studies will
be needed to more clearly determine the relative roles of mitophagy
and other proteostatic mechanisms in mitochondria, including their
importance in age-related declines in the heart.
Modulation of macroautophagy has shown a mix of positive and
negative results in various heart disease models; however, numerous
lines of evidence have shown that macroautophagy has an important
role in organismal and cardiac aging. A recent report found that genetic
over-expression of ATG5, a vital autophagy protein involved in
autophagosome formation, improved mitochondrial morphology,
respiratory rates, and extended lifespan in mice [188]. ATG5 has been
shown to have a pro-apoptotic function, and this activity in reducing
cancer deaths C57BL/6micemay be a longevity-promoting component.
Cardiac-speciﬁc knockdown of ATG5 in mice has conversely been
shown to accelerate aspects of aging in the heart, suggesting that au-
tophagy plays an important role in maintaining normal heart function
and mediating cardiac aging. Like normally aging mice, cardiac speciﬁc
ATG5mutants develop left ventricular hypertrophy, but they also devel-
op accelerated heart failure with decreased fractional shortening,
abnormal mitochondrial morphology, decreased respiratory capacity,
and die prematurely [175,189,190]. While themechanism bywhich au-
tophagy maintains cardiac function is not fully understood, fragmenta-
tion of mitochondria and accumulation of ubiquitinated proteins and
p62 in mice lacking ATG5 suggests that this is an essential protective
mechanism [189,191]. In agreement with this, a study performed on
cardiomyocyte cell lines found that induction of autophagy was protec-
tive against oxidative stress-induced protein aggregation, reduced
levels of protein ubiquitination, improved mitochondrial function, and
reduced cell death [175,191].
Inhibition of the mTOR pathway (see above) is well known to
increase autophagy and extend lifespan. In fact, the mTOR inhibitor
rapamycin is one of the few drugs available which can be used to
increase autophagy. Longevity studies with rapamycin and other
forms ofmTOR inhibition have reported increased autophagy in animals
across many studies [92,139,140,143], and offer further evidence that
autophagymay play a central role in aging. Even so, due to the difﬁculty
of speciﬁcally over-expressing autophagy components without
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autophagy can extend lifespan is not yet available.
10. Mitochondrial unfolded protein response
Themitochondrial unfolded protein response (UPRMT) is another as-
pect of protein quality control implicated in cardiac aging via its effects
on mitochondrial function. UPRMT was ﬁrst proposed in 1996, and de-
scribed as a stress response involving mitochondrial chaperones and
heat shock proteins [192]. Various models have been investigated to
help reduce the amount of stress that occurs in the mitochondria, help-
ing to decrease the UPRMT [17,193]. Dietary supplementation with tau-
rine, a key nutrient for cardiac health, was shown to decrease oxidative
stress and inhibit mitochondria-dependent cell apoptosis [193].
Prohibitins (Phb), highly conserved proteins in the mitochondria, have
pivotal roles in the UPRMT. Phbmake hetero-multimeric ring complexes
that help with propermitochondrial protein folding, ETC. assembly, and
the regulation of proteases [194,195]. Phb2 helps ensure that OPA1 is
functional for mitochondrial fusion. In a complex with DNAJC19, Phb2
is responsible for maintaining cardiolipin and mitochondrial cristae
structure for healthy mitochondrial function [195]. Other proteins in-
volved in this process are mtShp70, Hsp60, and Hsp10. Mitochondrial
Unfolded Response Elements 1 and 2 (MURE1 and MURE2) help
upregulate Hsp60 and ClpP during mitochondrial homeostasis [196].
Recently, the UPRMTwas investigated in an in vivomodel of electron
transport deﬁciency mice. Surf1−/− and litter mate control hearts were
investigated for their induction of UPRMT proteins under the constant
stress of COX assembly deﬁciency. The authors found signiﬁcant in-
creases in Lon and Trx2, with a trend of increased CHOP, all implicated
in the UPRMT, demonstrating the role that the mitochondrial UPRMT
canplay to help relievemitochondrial dysfunction inhearts in a stressed
environment [196]. This study was performed in young mice, leaving
the exact role of the UPRMT in aging still open; however, this remains
an area of active investigation [197,198]. CHOP, Lon, and Trx2 are key
proteins in the stress response pathways. CHOP is activated by the
marking of unfolded proteins by BiP/GRP78, helping to prevent aggre-
gation of the misfolded proteins [199]. Lon and Trx2 have recently
been shown to play a key role in decreasing ROS in the mitochondria
and preventing apoptosis within the cardiomyocytes. Recent work sug-
gests that Lon helps prevent ROS induced apoptosis in a hypoxia model,
and one can hypothesize that Lon would perform this role in any
stressed environmental situation, not only in hypoxia [200]. Trx2 has
been known to be important in preventing apoptosis, since Trx2 knock-
out mice are embryonically lethal. Work from the Min lab shows that
there is a decrease in Trx2 expression in human dilated cardiomyopathy
patients, and that mice with Trx2 deleted from their heart also develop
this disease [201]. The loss of Trx2 increased oxidative stress, apoptosis,
ﬁbrosis, and contractile dysfunction, due to Trx2 not being around for
decreasing ROS production or binding ASK1 to prevent apoptosis
[201]. This encourages the notion that an increased expression of Trx2
helps maintain a stable and healthy environment in stressed hearts by
decreasing ROS production and blocking mass apoptotic cell death
[201]. Another study using BXMmice demonstrated that the transcrip-
tional regulation and protein regulation of the same protein can vary in
theUPRMT in opposite directions [202]. Thus,while there is considerable
interest in UPRMT as a new and potentially underappreciated mecha-
nism of proteostasis, it is too early to know its signiﬁcance in normative
cardiac aging.
11. Mitochondrial targeted therapies
Due to the critical importance of mitochondria in insuring adequate
cellular energetics and function, there has been great interest in discov-
eringmitochondrially targeted therapies for various diseases and condi-
tions, including cardiac dysfunction and aging. Some of these therapies
attempt to decrease the oxidative stress in the mitochondrialenvironment [203], while others focus on structural components of
mitochondria [204–208]. It can be argued that CR and inhibition of
mTOR signaling can do both, and thus, these two interventions,
described above, and may also be considered to be mitochondrial
therapies.
11.1. Mitochondrial antioxidants
The triphenylalkylphosphonium ion (TPP+) has been conjugated to
coenzyme Q (MitoQ) and plastoquinone (SkQ1) to deliver these redox-
active compounds into the mitochondrial matrix, utilizing the negative
potential gradient across the innermitochondrialmembrane.MitoQhas
been shown to help maintain eNOS availability and reduce hyperten-
sion. MitoQ has been given together with losartan, an angiotensin
receptor blocker, that did not decrease ROS production in themitochon-
dria, but the combined therapy did lead to an improvement in cardio-
vascular function [207]. SkQ1 is another mitochondrial targeted
antioxidant that has been reported to extend lifespan in male BALB/c
mice and dwarf hamsters [209]. In the BALB/c mice there was also a re-
duction in age-related cardiac hypertrophy [209,210]. Pretreatment
with MitoQ and SkQ1 have both been shown to have beneﬁcial effects
in animal models of ischemia-induced cardiac dysfunction [211,212].
The role that mitochondrial-targeted antioxidants might be able to
play in protecting or repairing cardiac mitochondrial dysfunction in
aging is thus a promising area of study. CoQ10, amimic of a naturally oc-
curring antioxidant of the electron transport chain has also showed
promise improving mitochondrial function in the heart. Mouse studies
involving ApoA1−/− mice demonstrate that addition of CoQ10 im-
proves infarct size to that of a wild-type mouse [213]. Current human
studies using CoQ10 in dietary supplements in adults have hint at
improved health with an optimal diet [214,215], and clinical study in
children with primary mitochondrial diseases is underway [214,215].
11.2. Cardiolipin-targeted therapies
Two CL targeted drugs have been studied, TPP-n-ISA and SS-31. TPP-
n-ISA, studied primarily in brain injury and radiation, helped maintain
CL in a structural arrangement that makes peroxidation more difﬁcult
[208]. The Szeto–Schiller (SS) compounds are tetrapeptides that prefer-
entially concentrate in themitochondrial innermembrane independent
of the mitochondrial potential gradient. SS-31 (or as an acetate salt
MTP-131, aka Bendavia™), the best studied of these, has been shown
to reduce ROS levels and prevent ischemia–reperfusion injury in a vari-
ety of infarct models [206,216]. In our laboratory, we have found SS-31
to be protective of angiotensin II induced cardiac hypertrophy, aswell as
G alpha q-induced cardiac failure [217]. The protective effect of SS31 in
the TAC model of heart failure was as great as that of mCAT, and con-
ferred an even more complete protection of failure-related proteomic
alterations than did mCAT [218]. It has recently been shown that
SS-31 targets CL, altering the CL/cytochrome c interaction to optimize
electron transfer, inhibit ROS generation and cytochrome c peroxidase
activity. In a number of disease models SS-31 appears to help maintain
mitochondrial cristae density, presumably by preserving the
tetralinoleoyl isoform of CL which is vital to maintaining cristae curva-
ture [204,205,219]. By stabilizing the CL-cytochrome c interaction,
SS-31 may also prevent the pro-apoptotic activity of cytochrome c,
although this has not been proven. In its clinical formulation, Bendavia,
SS-31 is currently in multiple phase II studies, including a study to ex-
amine its impact to improve outcome in patients with acutemyocardial
infarction [220], as well as for treatment of patients with mitochondrial
myopathy in primary mitochondrial disease, including Barth syndrome
(NCT02367014).
The application of mitochondrially targeted therapies appears to be
an exciting area of growth, as additional druggable targets to protect
or improve the function of this important organelle are discovered.
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As previously mentioned above, the regulation of NAD is key to
allowing the sirtuins pathways to maintain their function, which helps
with healthspan and lifespan. With this idea, more NAD+/NADH
therapies are being created. In a study of gas-1mutant worms, nicotinic
acid (NA) and resveratrol both improved survival of the worms [221].
NA helped decrease the amount of ROS in the worms system and it
was suggested that the NA increased NAD+ pools which can helpmain-
tain Sirt3 acetylation patterns. Nicotinamide riboside can also increase
the NAD+ pool without activating Sirt3, but providing comparable
beneﬁts [222]. PARP-1 inhibitors, Phe and PJ34, demonstrated improved
mitochondrial content and membrane potential in Complex I mutant
human ﬁbroblasts [222]. Both inhibitors increase the transcription of
mitochondrially encoded respiratory complexes, relaying a better
survival of the cells.
12. Conclusions
Mitochondrial dysfunction is a hallmark of cardiac aging,with amul-
titude of interactions that are involved in health and disease. Because of
its central role in cellular energetics, mitochondria play important roles
in multiple signaling pathways. While we have described some of these
functions in mTOR, IGF-1, and sirtuin signaling, the complexities of
these interactions leave many questions for future investigation. A
better understanding of the underlying biology will help to elucidate
the multiple roles that mitochondrial dysfunction may play in cardiac
aging and disease. Greater mechanistic insights will also allow develop-
ment of novel mitochondrial targeted therapies to attenuate or reverse
mitochondrial dysfunction and cardiac aging.
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